AMM: Antidepressant Medication Management
Acute phase: percentage remaining on antidepressant for 12 weeks. Continuation phase: 6 months. Both rates reported.
Measure description
Acute phase: percentage remaining on antidepressant for 12 weeks. Continuation phase: 6 months. Both rates reported.
Eligible population
Members with major depression starting antidepressant
Performance drivers
Premature discontinuation of antidepressants (most stop within 30 days) drives recurrence.
Documentation & PA strategy
Document MDD diagnosis (not adjustment d/o), starting therapy, follow-up plan at 12 weeks + 6 months. Don't bill MDD if not warranted.
Why HEDIS matters for prior authorization
Health plans align prior authorization criteria with HEDIS measures: documenting your patient meets the HEDIS definition often streamlines or eliminates PA hurdles. For Medicare Advantage in particular, plans are heavily incentivized via Star Ratings to push members and providers toward measure compliance, which translates into faster approvals for measure-aligned services.
Frequently asked questions
What does HEDIS measure AMM measure?
Acute phase: percentage remaining on antidepressant for 12 weeks. Continuation phase: 6 months. Both rates reported.
What drives performance on this measure?
Premature discontinuation of antidepressants (most stop within 30 days) drives recurrence.
How should clinicians document for this measure?
Document MDD diagnosis (not adjustment d/o), starting therapy, follow-up plan at 12 weeks + 6 months. Don't bill MDD if not warranted.
What is the eligible population?
Members with major depression starting antidepressant
Streamline AMM workflow with ApprovalHelp
ApprovalHelp automates clinical PA, appeals, and HEDIS-aligned documentation. no setup fee.
Get started →Contact: hello@approvalhelp.com